Switch theme
Sign up to access all valuation multiples
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
2014
14
LTM Revenue n/a
LTM EBITDA n/a
$54.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genenta Science has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Genenta Science achieved revenue of n/a and an EBITDA of -$12.2M.
Genenta Science expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genenta Science valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | -$5.7M | -$11.5M | -$12.2M | n/a | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | -Infinity% | NaN% | XXX |
| Net Profit | -$5.8M | -$8.8M | -$12.1M | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | -Infinity% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Genenta Science's stock price is EUR 4 (or $4).
Genenta Science has current market cap of EUR 69.0M (or $71.9M), and EV of EUR 52.1M (or $54.3M).
See Genenta Science trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $54.3M | $71.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Genenta Science has market cap of $71.9M and EV of $54.3M.
Genenta Science's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Genenta Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Genenta Science and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $54.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -4.5x | XXX | XXX | XXX |
| P/E | -5.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGenenta Science's NTM/LTM revenue growth is n/a
Genenta Science's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Genenta Science's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Genenta Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Genenta Science and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genenta Science acquired XXX companies to date.
Last acquisition by Genenta Science was XXXXXXXX, XXXXX XXXXX XXXXXX . Genenta Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Genenta Science founded? | Genenta Science was founded in 2014. |
| Where is Genenta Science headquartered? | Genenta Science is headquartered in Germany. |
| How many employees does Genenta Science have? | As of today, Genenta Science has 14 employees. |
| Who is the CEO of Genenta Science? | Genenta Science's CEO is Mr. Pierluigi Paracchi. |
| Is Genenta Science publicy listed? | Yes, Genenta Science is a public company listed on BER. |
| What is the stock symbol of Genenta Science? | Genenta Science trades under K5F ticker. |
| When did Genenta Science go public? | Genenta Science went public in 2021. |
| Who are competitors of Genenta Science? | Similar companies to Genenta Science include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Genenta Science? | Genenta Science's current market cap is $71.9M |
| Is Genenta Science profitable? | Yes, Genenta Science is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
